<DOC>
	<DOCNO>NCT01436396</DOCNO>
	<brief_summary>The study design evaluate whether first CYD dengue vaccination administer concomitantly Stamaril® yellow fever vaccine day visit , 2 different site administration . Primary Objective : - To demonstrate non-inferiority immune response Yellow Fever flavivirus ( FV ) -naïve subject baseline receive one dose Stamaril vaccine administer concomitantly first dose CYD dengue vaccine compare subject receive one dose Stamaril vaccine concomitantly placebo . Secondary Objectives : - To assess non-inferiority yellow fever immune response 28 day post-Stamaril vaccination base seroconversion rate regardless FV status subject baseline . - To describe safety Stamaril vaccine administer concomitantly first dose CYD dengue vaccine , Stamaril administer concomitantly placebo . - To describe safety CYD dengue vaccine first dose CYD dengue vaccine administer concomitantly Stamaril vaccine CYD vaccine administer alone .</brief_summary>
	<brief_title>Study Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine Healthy Toddlers</brief_title>
	<detailed_description>All participant receive total 8 injection study . Vaccine immunogenicity assessment dengue neutralize antibody perform randomized subset participant . All participant followed-up safety study 6 month last CYD dengue vaccination .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 12 13 month day inclusion . Born full term pregnancy ( ≥37 week ) birth weight ≥2.5 kg report parent/legally acceptable representative . Subject good health , base medical history physical examination . Subject complete his/her vaccination schedule accord official immunization calendar Colombia and/or Peru , respectively . Informed consent form sign dated parent ( ) legally acceptable representative ( 2 independent witness require local regulation ) . Subject parent/legally acceptable representative/tutor able attend schedule visit comply trial procedure . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Planned receipt vaccine 4 week follow first trial vaccination . Previous vaccination yellow fever ( YF ) , hepatitis A , measles , mumps rubella . Receipt blood bloodderived product past 3 month might interfere assessment immune response . Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 week longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Personal known seropositivity human immunodeficiency virus ( HIV ) report parent/legally acceptable representative . History previous maternal vaccination YF report parent/legally acceptable representative . Personal history YF dengue infection/disease report parent/legally acceptable representative . Known systemic hypersensitivity vaccine component vaccine use trial , history lifethreatening reaction vaccine use trial vaccine contain substance . History contraindication receipt vaccine contain component Stamaril ( yellow fever vaccine ) , measles , mumps rubella vaccine , hepatitis A vaccine , pneumococcal conjugate vaccine diphtheria ( D ) toxoid , tetanus ( T ) toxoid , pertussis toxoid ( PT ) , filamentous hemagglutinin ( FHA ) , polyribosylribitol phosphate ( PRP ) polio DTP vaccine ( e.g. , DTwP ) . Thrombocytopenia , report parent/legally acceptable representative . Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular ( IM ) vaccination . History central nervous system disorder disease , include seizure . Personal history thymic pathology ( e.g. , thymoma ) , and/or thymectomy . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . Identified child ( adopted natural ) Investigator employee Investigator study center , direct involvement propose study study direction Investigator study center .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>13 Months</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>CYD Dengue Vaccines</keyword>
	<keyword>Yellow Fever</keyword>
	<keyword>Stamaril®</keyword>
	<keyword>Flavivirus Infections</keyword>
</DOC>